Kornimate/medical-research-clean huggingface dataset:
impact of intravascular ultrasound guidance on the outcomes of xience prime stents in long lesions (ivus-xpl study): retrospective and prospective follow-up study

Conditions: Myocardial Ischemia(Implanted Drug-eluting Stents Because of Ischemic Heart Disease(Stable Angina, Acute Coronary Syndrome))

Summary: the investigator aimed to evaluate the long-term (up to 10 years) follow-up of the patients who enrolled the ivus-xpl study (impact of intravascular ultrasound guidance on the outcomes of xience prime stents in long lesions), which was shown the superiority of ivus-guided stent implantation at 1 year in terms of major adverse cardiac events.

the investigator will follow-up (up to 10 years) the patients who enrolled the ivus-xpl study (impact of intravascular ultrasound guidance on the outcomes of xience prime stents in long lesions).

Eligibility criteria:
inclusion criteria: * 1. the patients who enrolled in the xpl-ivus study. * 2. provision of informed consent exclusion criteria: * 1. this observational study does not have any specific exclusion criteria.

Keywords: clinical outcome; ivus; stent
clinical outcome modelling of rapid dynamics in acute stroke

Conditions: Stroke

Summary: stroke - still the second commonest cause of death and principal cause of adult neurological disability in the western world - is characterised by rapid changes over time and marked variability in outcomes. a patient may improve or deteriorate over minutes, and the resultant disability may range from an obvious complete paralysis to subtle, task dependent incoordination of a single limb. unlike many other neurological disorders, stroke can be exquisitely sensitive to prompt and intelligently tailored treatment, rewarding innovation in the delivery of care with real-world, tangible impact on patient outcomes. optimal treatment therefore requires both detailed characterisation of the patient's clinical picture and its pattern of change over time. arguably the most important aspect of the patient's clinical picture -- body movement -- remains remarkably poorly documented: quantified only subjectively and at infrequent intervals in the patient's clinical evolution. the combination of artificial intelligence with high-performance computing now enables automatic extraction of a patient's skeletal frame resolved down to major joints, like that of a stick-man, to be delivered simply, safely, and inexpensively, without the use of cumbersome body worn markers. central to this technology is patient privacy, with the skeletal frame extracted in real time, ensuring no video data, from which patients can be identified, to be stored or transmitted by the device. our motion categorisation system -- mocat -- will be used to study the rapid dynamics of acute stroke, seamlessly embedded in the clinical stream. by quantifying the change in motor deficit over time we shall examine the relationship between these trajectories with clinical outcomes and develop predictive models that can support clinical management and optimise service delivery.


Eligibility criteria:
inclusion criteria: * putative diagnosis of an acute stroke * admission on the stroke unit exclusion criteria: * under 18 years of age
mesenteric approach vs. conventional approach for pancreatic cancer

Conditions: Pancreatic Ductal Adenocarcinoma; Pancreaticoduodenectomy; Mesenteric Approach

Summary: the aim of this study is to evaluate the advantage of mesenteric approach during pancreaticoduodenectomy (pd) for pancreatic ductal adenocarcinoma (pdac). the design of this study is multicenter randomized clinical trial, comparing oncological and surgical outcomes between mesenteric approach and conventional approach during pd for pdac.

mesenteric approach starts from dissection of lymph nodes around the superior mesenteric artery (sma) and finally performs kocher's maneuver during pd. the aims of this approach are 1) decrease of intraoperative blood loss volume, 2) increase of r0 rate, and 3) prevention of squeezing cancer cells out into the vessels. however, there have been no evidence of the efficacy of this procedure. therefore, the aim of this study is to evaluate the efficacy of mesenteric approach during pd for pdac, by multicenter randomized clinical trial comparing oncological and surgical outcomes between mesenteric approach and conventional approach during pd for pdac.

Eligibility criteria:
inclusion criteria: 1. patient who are scheduled to undergo pancreaticoduodenectomy for resectable or borderline resectable (only portal vein invasion) pancreatic ductal adenocarcinoma. 2. patients whose eastern cooperative oncology group performance status are 0 or 1. 3. patients who are 20 years or older. 4. patients who have adequate organ function. 5. patients who understand sufficiently the study to provide written informed consent exclusion criteria: 1. patients who have severe ischemic cardiovascular disease 2. patients who have liver cirrhosis or active hepatitis 3. patients who need oxygen due to interstitial pneumonia or lung fibrosis 4. patients who receive dialysis due to chronic renal failure 5. patients who need surrounding organ resection 6. patients who need artery reconstruction 7. patients who are diagnosed as positive para-aortic lymph node metastases based on preoperative imaging 8. patients who have active multiple cancer that is thought to influence the occurrence of adverse events 9. patients who take steroid for the long period that is thought to influence the occurrence of adverse events 10. patients who undergo laparoscopic or laparoscopy-assisted pancreaticoduodenectomy 11. patients who cannot understand ths study due to psychotic disease or psychological symptoms 12. patients whose preoperative biopsy tissues are diagnosed as other pathological findings than pancreatic ductal adenocarcinoma 13. patients who underwent gastrectomy or colon/ rectum resection previously 14. patients who have severe drug allergy to iodine and gadolinium
study of everolimus (rad001) in patients with recurrent glioblastoma multiforme (gbm)

Conditions: Glioblastoma Multiforme

Summary: this study will define the safety and efficacy of everolimus (rad001) administered daily in patients with glioblastoma multiforme (gbm)

this was a multicenter, open label, randomized study of rad001 dosed daily in patients with recurrent gbm. the study was conducted with 2 parallel groups of patients. group 1 was designed to study the biological effects of rad001 in patients scheduled to undergo salvage surgical resection, and group 2 was to enroll patients who were not scheduled for surgery. patients in group 1 were randomly assigned to one of three pre-surgery treatment groups (0, 5 or 10 mg/day rad001 for 7 days). all patients in group 2 were to receive a fixed daily dose of 10 mg/day oral rad001.

Eligibility criteria:
inclusion criteria: * age 18 years of age or older * histologically confirmed glioblastoma multiforme (gbm) * radiographic evidence of disease progression * patients must have evaluable contrast enhancing tumor * availability of paraffin blocks or unstained pathology slides for biomarker studies * karnofsky performance status of greater than or equal to 60% exclusion criteria: * prior treatment with mammalian target of rapamycin (mtor) inhibitor * history of another malignancy within 3 years * cardiac pacemaker * ferromagnetic metal implants other than those approves as safe for use in magnetic resonance imaging (mri) scanners * claustrophobia * obesity * unstable systemic diseases * elevated cholesterol or triglycerides * radiation therapy or cytotoxic chemotherapy \<=4 weeks prior to study enrollment. patient must have recovered from the toxic effects of a prior chemotherapy. * patients must be off all enzyme inducing anticonvulsants for at least 2 week before study enrollment can occur * need for increasing dose of steroids. patients on a stable or tapering dose of steroids \>=7 days were permitted.

Keywords: glioblastoma multiforme, gbm, rad001, rad
study of an approved drug with a statin (a medication that lowers cholesterol levels) as compared to statin therapy alone in patients with high cholesterol (0653-040)

Conditions: Hypercholesterolemia

Summary: the purpose of this 6-week study is to compare the reduction in specific levels of cholesterol in patients with high cholesterol.

the duration of treatment is 6 weeks.

Eligibility criteria:
inclusion criteria: * high cholesterol levels that are identified by specific laboratory values exclusion criteria: * active liver disease * any condition or situation which would interfere with participation
use of decitabine in myelodysplastic syndrome (mds) following azacitidine (aza) failure

Conditions: Acute Myeloid Leukemia; Chronic Myelomonocytic Leukemia; Myelodysplastic Syndrome

Summary: the purpose of this study is to assess the response rate at 6 months in myelodysplastic syndrome (mds) patients, chronic myelomonocytic leukaemia (cmml-2) patients, and acute myeloid leukaemia (aml) patients with up to 30% bone marrow blasts, treated with low-dose decitabine who have previously failed therapy with 5-azacitidine.


Eligibility criteria:
inclusion criteria: 1. written signed informed consent. 2. ≥18 years of age. 3. diagnosed mds with 5% or more marrow blasts and ipss risk intermediate 2 or high risk; or chronic myelomonocytic leukemia (cmml-2); or aml with 20-30% bone marrow blasts. 4. patients who have failed therapy with azacitidine. 5. performance status 0-2 (ecog scale). 6. adequate hepatic (bilirubin \< 1.5 x uln or ast\< 2.5 x uln) and renal functions (creatinine \<1.5 x uln). exclusion criteria: 1. nursing and pregnant females. 2. females of childbearing potential and males not willing to practice an effective method of contraception whilst receiving decitabine and for 2 months after the last infusion. 3. patients with previous malignancy or concurrent malignancy. 4. uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure and unstable angina pectoris. 5. ongoing oral corticosteroids are not permitted. however, use of corticosteroids (topical and inhaled) is permitted and prophylactic steroids are allowed for transfusion reactions. 6. patients who have received any investigational agent within the 30 days preceding the first dose of study drug. 7. patients who have received prior intensive combination chemotherapy or high-dose cytarabine (\>/= 1g/m\*2 per dose). (prior biologic therapies, targeted therapies and single agent chemotherapy are allowed). 8. patients who have an active viral or bacterial infection. note: no patient is allowed to enter the study unless infections have been fully treated and the patient has remained afebrile for 7 days without antibiotics. 9. patients who have concurrent autoimmune hemolytic anemia or immune thrombocytopenia. 10. patients who have previously been treated with decitabine. 11. patients who have known positive serology for hiv. 12. patients with a condition that may be unable to comply with the treatment and monitoring requirements of the study.
augmenting buried in treasures workshop (bit) with in-home decluttering practice for individuals with hoarding disorder

Conditions: Hoarding Disorder

Summary: patients participate in buried in treasures workshop (bit) that has been shown to improve symptoms of hoarding disorder. to target levels of clutter, the investigators are testing an intervention to add in-home decluttering practice to the bit workshop.


Eligibility criteria:
inclusion criteria: * 18 years or older at consent * primary hoarding disorder, saving inventory revised greater than or equal to 40. * clutter image rating scale greater than or equal to 3 and less than or equal to 7. * low risk for eviction * english speaking * will and able to understand and complete consent procedures exclusion criteria: * hoarding disorder not primary * severely depressed individuals; hamilton depressions rating scale greater than 30 or judged clinically to be at risk of suicide with columbia suicide severity scale * unable or unwilling to allow study staff into home for home assessment or a clutter image rating score of less than 2 or greater than 7. * at risk for eviction * animal hoarding or squalor of any kind
etmr one: an international registry and research platform for children with embryonal tumor with multilayer rosettes

Conditions: Embryonal Tumor With Multilayered Rosettes

Summary: this research is being done to find out more information about a brain tumor called embryonal tumor with multilayer rosettes (etmr) by collecting medical information from children who have this disease. the purpose of this research study is to create and maintain a research database for patients with etmr. the database will include information about occurrence rates, patient information, tumor tissue information, and response to treatment. this will help advance our understanding of this rare disease. in addition, this study will include obtaining survival data and evaluating therapeutic response to expert consensus therapy, and procuring patient tumor tissue.

all patients with etmr are eligible for inclusion within the registry, regardless of their disease status or treatment plan. epidemiologic, clinical, and molecular data from each patient will be obtained following enrollment. patients will then be followed longitudinally to obtain clinical outcome data. in an effort to best achieve the registry's secondary objectives, it is preferable, but not required, for patients to be registered soon after their diagnosis, prior to the initiation of any tumor-directed therapy. this registry protocol contains recommendations for a consensus therapy derived from the etmr medical literature, the investigators' own experience, and clinical data from other infant brain tumor protocols. the recommended therapy can thus not be viewed as investigational, but rather as a consensus recommendation derived from available data. while not mandated, it is strongly encouraged that patients enrolled in the registry be treated according to the recommended consensus therapy, as this will facilitate the prospective evaluation of etmr patients using a uniform treatment approach.

Eligibility criteria:
inclusion criteria: 1. patients of any age 2. patients must have either a histologically confirmed primary intracranial cns embryonal tumor with multilayer rosettes (as agreed upon by central review or local pathologist or 3. patients must have tumor tissue that possesses c19mc amplification . central review is not required (but is strongly recommended) if the patient's tumor does not demonstrate c19mc amplification. 4. patients may be enrolled at point following diagnosis

Keywords: embryonal multilayer rosettes cns tumor
dermacyd delicata breeze - photo evaluation

Conditions: Healthy

Summary: the purpose of this study is to prove the absence of photo irritation and photo sensitivity potential of the product dermacyd breeze.


Eligibility criteria:
inclusion criteria: * phototype skin ii and iii * integral skin test in the region exclusion criteria: * lactation or gestation * use of antiinflammatory and/or immunosuppression drugs 15 days before the selection * diseases which can cause immunity decrease, such as hiv, diabetes * use of drug photosensitizer * history of sensitivity or irritation for topic products * active cutaneous disease which can change the study results * history or photodermatosis active * family or personal antecedent of cutaneous photoinduced neoplasias * presence of a precursor lesion of cutaneous neoplasia, such as nevus melanocyte and keratoses actinium * intense solar exposure in the study area * use of new drugs or cosmetics during the study the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Keywords: hygiene
safety and efficacy study of bimatoprost in japanese patients with chemotherapy-induced eyelash hypotrichosis

Conditions: Eyelash Hypotrichosis

Summary: this study will evaluate the safety and efficacy of bimatoprost solution 0.03% compared with vehicle in japanese adults with hypotrichosis of the eyelashes following chemotherapy treatment.


Eligibility criteria:
inclusion criteria: * have inadequate eyelashes due to chemotherapy treatment * treated for solid tumors such as breast or colorectal cancer in early stages where the cancer has not spread outside the primary organ (eg, stage 1, 2 or 3a for breast cancer) * have completed chemotherapy treatment for at least 4 weeks but not more than 24 weeks and all side effects related to chemotherapy are recovered, improved or maintained, with the exception of hair loss exclusion criteria: * any disease/infection/abnormality of the eye or area around the eye * any ocular surgery within 3 months or anticipated need for ocular surgery during the study * any permanent eyeliner or implants of any kind or anticipated use of false eyelashes * any semi-permanent eyelash tint, dye, curl or eyelash extension application within 3 months * use of any over-the-counter eyelash growth product within 6 months or any use of prescription eyelash growth products * use of treatments which may affect hair growth (eg, minoxidil) within 6 months except for prior chemotherapy
safety, tolerability, and pharmacokinetics of hsk21542 in healthy volunteers

Conditions: Postoperative Pain; Chronic Pain

Summary: this is a a phase 1, randomized, double-blind, placebo-controlled, single-ascending-dose study to investigate the safety, tolerability, and pharmacokinetics of a kappa receptor agonist hsk21542 in healthy volunteers. the study will enroll approximately 50 adults. the anticipated study duration will be up to 6 months.


Eligibility criteria:
inclusion criteria: * healthy male and female subjects, age 18-45 years; * bmi between 18.0-27.0 kg/m2 * determined by investigator to be in general good health according to medical history, comprehensive physical examination; * understanding of the nature, significance, potential benefits and risks of the trial, understanding of the procedures and be able to provide written informed consent voluntarily ; * good communication with investigators, compliance with the study requirements and willingness to stay in phase i clinical trial ward as required. exclusion criteria: * anyone who has suffered or is currently suffering from any serious diseases, that may interfere with the results of the trial; * determined by investigator to be abnormal with clinical significance in physical examination, vital signs monitoring, electrocardiogram, chest radiograph, laboratory examination; * hbsag positive, hcv antibody positive, treponema pallidum antibody positive, or hiv antibody positive; * qtcf \> 450ms; * allergic constitution; * intolerance of venipuncture and/or history of haemorrhage or needle fainting; * drug or alcohol abuse; * have used any prescription, over-the-counter, chinese herbal medicine or health products within 14 days; * blood donation or massive bleeding within 3 months (greater than 450 ml); * participants in any drug clinical trial within 3 months. * birth planning in the next six months.

Keywords: pain postoperative pain
a dose-finding study evaluating safety and efficacy in patients with chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the purpose of the study is to determine the appropriate dose of fluticasone propionate/formoterol fumarate that is closest to advair diskus (fluticasone propionate/salmeterol xinafoate using pulmonary function, safety, and levels of study drug in blood plasma in patients with chronic obstructive pulmonary disease.


Eligibility criteria:
inclusion criteria: * diagnosis of copd * female of child-bearing potential to use adequate birth control * smoker or ex-smoker with history of at least 10 years of smoking at least one pack of cigarettes per day * meet lung function requirements exclusion criteria: * diagnosis of asthma * other significant disease than copd * pregnant or lactating female * female planning to become pregnant

Keywords: chronic obstructive pulmonary disease copd safety efficacy pharmacokinetic dose-finding
a randomized double-blind placebo controlled trial to determine the status of post knee chondroplasty patients administered theramine versus placebo in addition to post surgery analgesics

Conditions: Knee Pain; Knee Chondroplasty

Summary: the purpose of this study will be to show the patient response to analgesics taken post surgery when taken in combination with theramine as opposed to theramine-like placebo. the data collected will be used to show that patients have a shorter and lower post operative pain measurement and the time to discontinuation of analgesics is less in the active comparator group.

no other decription

Eligibility criteria:
inclusion criteria: * diagnosed knee pain requiring chondroplasty knee arthroscopic surgery. * men and non-pregnant, non-lactating women over the age of 18 and under the age of 75, able to read, understand and sign english-language informed consent. * if using psychoactive medication which might have analgesic effects, (i.e. anti-depressants or anti-consultants), treatment must be stable for at least three (3) months prior to study. * for men and women of child-bearing potential, must be willing to use adequate contraception and not be pregnant or impregnate their partner during the entire time of study. * must be willing to commit to all clinical visits during study-related procedures. * require use of narcotics for pain relief. exclusion criteria: * patients with significant neurologic impairment, as diagnosed on screening physical examination. * patients not fluent in english. * patients currently involved in a workman's compensation case related to this procedure. * receipt of an oral intramuscular or soft-tissue injection of corticosteroid within one (1) month prior to screening. * history of substance abuse. * history of malignancy, other than basal or squamous cell of the skin within the last 5 years. * tibial plateau fracture within 6 months prior to surgery.

Keywords: prescription medical food theramine knee surgery
adding shock wave therapy to kinesio taping improves carpal tunnel syndrome in physical therapist females.

Conditions: Physiopathology

Summary: purpose: to investigate the effect of adding shock wave therapy to kinesio taping on relieving carpal tunnel syndrome symptoms in physical therapist females. background: shockwave therapy is a popular non-invasive therapeutic modality in the medical field for the treatment of numerous musculoskeletal disorders. shockwaves can generate interstitial and extracellular responses, producing many beneficial effects such as: pain relief, vascularization, protein biosynthesis, cell proliferation, neuro and chondroprotection, and destruction of calcium deposits in musculoskeletal structures. shockwave combined with conventional physiotherapy is an effective noninvasive treatment for mild-to-moderate carpal tunnel syndrome that produces greater and longer-lasting results than conventional physiotherapy alone hypotheses: adding shock wave therapy to kinesio taping has positive effects on carpal tunnel syndrome in physical therapist females. research question: does adding shock wave therapy to kinesio taping has positive effects on carpal tunnel syndrome in physical therapist females?


Eligibility criteria:
inclusion criteria: * patients aged between 20 and 40 years * diagnosed as having mild and moderate carpal tunnel syndrome through clinical parameters and nerve conduction studies (ncss), exclusion criteria: - having any systemic diseases such as renal failure, peptic ulcer, diabetes mellitus, hypothyroidism, coagulopathy, inflammatory rheumatic disease, having a cardiac pacemaker, cervical radiculopathy, polyneuropathy or brachial plexopathy, systemic corticosteroid use, fracture or trauma history in the forearm and wrist pregnancy and lactation, having received a carpal tunnel syndrome surgery, thoracic outlet syndrome or severe carpal tunnel syndrome.

Keywords: shockwave carpel tunnel